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ABSTRACT 
Background: Overall survivability in breast cancer has improved in the past decade yet 
African American Black (AA/B) patients still experience disproportionately higher 
mortality compared to whites, with some studies showing a widening disparity. 
Emerging evidence suggests that comorbidities might play an important role in 
explaining this disparity. Few studies to date, however, have examined if co-
mordbidities tend to be linked more with other causes of death versus breast cancer 
pointing towards the need of better controlling of existing co-morbidities. Traditional 
methods of assessing cause-specific deaths, however, are prone to error in cause-
specific outcomes due to censoring all other causes of deaths. Methods: We analyzed 
data from the Connecticut SEER tumor registry (n=2558) with equivalent proportions of 
AA/B and white patients, and a random subset (n=416) of these patients for whom a 
medical record review was conducted, seventeen prognostic clinical conditions (e.g., 
heart disease, diabetes) listed in the Charlson Co-Morbidity Index (CCI) were identified. 
We compared estimates of breast cancer specific mortality using Cox Proportional 
Hazard Survival Analysis to calculate hazard ratios (HR) with the Subdistributional 
Hazard method (SD-HR), which calculates hazard ratios taking into account other 
causes of death. Results: AA/B patients were less likely to have no co-morbidities 
compared to whites (58.9% vs. 82.8 %, respectively, p=<.0001). Among patients with 
local stage disease, the traditional Cox Method showed comparable breast cancer 
specific mortality risk for AA/B compared to whites in the full sample (HR=0.97 95% CI 
0.87-1.08) whereas the subdistributional method showed an increase breast cancer 
mortality risk for African Americans (SD-HR=1.43 95% CI 0.97-2.12). For regional 
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stage, both estimates were statistically significant but a greater effect was observed 
using the subdistributional method (SD-HR=1.31 95% CI 1.13-1.52 and SD-HR=1.84 
95% CI 0.1.34-2.53). When the CCI score was added to analyses in the sub-sample, a 
substantially reduced risk of breast cancer-specific death was observed for AA/B 
patients compared to whites (SD-HR=0.17 95% CI 0.03-0.92) but no difference in risk 
was observed when using the Cox Method (HR=0.97 95% CI 0.70-1.17). For patients 
with Regional stage in the sub-sample, adding the CCI score to the Cox model revealed 
no difference in breast cancer specific mortality (HR=0.98 95% CI 0.67-1.43) but was 
suggestive of a higher risk when using the sub-distributional analysis (SD-HR=1.99 95% 
CI 0.90-4.345). Conclusion: In the larger sample, a higher risk of breast cancer specific 
mortality for AA/B patients was observed when using the sub-distribution analytical 
method compared to the traditional survival analysis. Adding the Charlson Co-morbidity 
Index into models, however, revealed a reduced risk of breast cancer specific death for 
those with local disease suggesting that existing medical conditions might drive 
mortality when the cancer burden is lower. 
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Introduction: 
Breast cancer survival disparities are puzzling given that African American Black 
(AA/B) women are less likely to develop breast cancer compared to white women. The 
Centers for Disease Control (CDC) reports that breast cancer is the second leading 
cause of cancer deaths in African Americans (Black) women.3 Although mortality rates 
from breast cancer have declined over the past decade for all ethnic groups, AA/B 
continue to suffer a higher burden of death.3 For decades, African-American/Black 
(AA/B) breast cancer patients between the ages of 45-60 have had a 60% greater death 
rate than their white counterparts1. Eliminating this racial survival disparity in breast 
cancer is a public health priority. By establishing sufficient evidence, targeted 
interventions can be created at the health care level to improve survival rates.   
 Numerous studies have implicated the three-fold greater prevalence of the 
aggressive Triple-Negative Breast Cancer (TNBC) subtype (i.e., HER2-ER-PR-) in 
African American/Black (AA/B), compared to non-Hispanic Whites, in the differential 
poor survival prognosis2. One TNBC study, however, found that the presence of co-
morbidities at diagnosis was comparably predictive of mortality as TNBC.1 Those 
findings are consistent with emerging data that AA/B breast cancer patients with specific 
types of co-morbidities might be at disproportionate risk of mortality.7,26 Though the 
impact of co-morbidities in survival in breast cancer patients has been studied, analyses 
of competing risk of death in the presence of existing co-morbidities has not been 
assessed to date. That is, given relatively higher rates of co-morbidities among African-
Americans 3,7, it is of interest to determine if African-American breast cancer patients 
are more likely to die from other causes of death (e.g., heart disease) versus breast 
cancer, and if differences in cause of death suggest the need for better control of co-
morbidities. Traditional methods of assessing cause-specific death, however, are prone 
to underestimate the cause of interest (e.g., death from breast cancer) because all other 
causes of death are censored.46-47In our study, therefore, we will compare breast-
cancer specific mortality using the traditional statistical method (i.e., Cox Proportional 
Hazards Survival Analysis) versus the subdistributional hazard ratio (SHR) model in 
which mortality for breast cancer as well as other causes of death are estimated. 
Additionally, use of the SHR model is appropriate in study samples consisting of older 
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patients where competing causes of death may be relatively high such is the case in 
cancer patients, a disease of aging.46-47Therefore, it is important to consider models that 
take in account competing events when estimating cause-specific mortality from breast 
cancer. 
 
Research Aims:   
 The primary aim of this research project is to conduct a survival analysis using the 
subdistributional competing risks approach versus the traditional technique in a large 
sample of breast cancer patients (n=2558) from the Connecticut Tumor Registry. We 
will determine whether mortality is due to any cause of death or breast cancer as the 
cause of deathSecond, in a sub-set of this sample (n=416) for whom we conducted a 
chart review, we will perform a competing risks analysis accounting for existing co-
morbidities ascertained using the Charlson Co-Morbidity Index (CCI) measurement tool.  
 
Background and Significance: 
African-American status continues to be an independent predictor of poor breast 
cancer outcome, even after accounting for socioeconomic factors (SES), inadequate 
health care access9 and controlling for common treatment. While there is evidence that 
reduced accessibility to healthcare and delays in treatment can explain survival 
disparities,10-12 findings from a large cooperative national clinical trial with nearly 
identical treatment and conditions, African American/black ethnicity still remained an 
independent predictor of breast cancer outcomes13 suggesting that underlying biological 
disease or other clinical factors, such as co-morbidities at diagnosis might play a role.  
Competing Risks of Death. By analyzing both subdistributional and traditional cause-
specific models, we can compare their ability to estimate specific causes of mortality. 
Some studies have indicated that since elder population (age>65) have a higher risk of 
dying from any cause, rates of death from breast cancer might be erroneously 
estimated in traditional analyses that do not account for other causes of death in 
analyses.46-47 That is, AA/B breast cancer patients actually less prone to death from 
breast cancer than are white patients because AA/B patients are dying disproportionally 
more from other causes?  
 3 
Traditional analyses tend to show that AA/B patients are more likely to die from breast 
cancer than whites, but that finding might be questioned when non-breast cancer 
deaths are censored in traditional survival analyses. Examining this question is further 
complicated if the age at diagnosis differs meaningfully between groups. Given the 
effects of age on breast cancer incidents, death often occurs in the presence of 
competing risk factors such as heart disease or diabetes.5 Because AA/B breast cancer 
patients tend to be diagnosed at earlier ages, then the likelihood of a comorbid condition 
could also differ. Generally in older breast cancer patients, death occurs in the presence 
of competing risk factors such as, for example, heart disease or diabetes.5 
The likelihood of erroneous estimation of breast cancer specific mortality using 
the traditional methods of analysis, such as the Kaplan-Meier method and Cox 
Proportional Hazards Survival Analysis, is due to the stipulation of a binary outcome 
variable: those who experience the event of interest (e.g., breast cancer), and those 
who do not. Those who do not experience the event are labeled censored, which 
includes those who are presumed alive and those who died from a different cause. 6,48 
Understanding the reasons behind the greater mortality in African-American breast 
cancer patients requires analyzing the death from other causes as well.5  
 
Co-Morbidities and Mortality. In breast cancer patients older than 50 years, non-
cancer mortality exceeds breast cancer mortality. Severe co-morbidities in early stage 
breast cancer has been associated with all-cause mortality and breast cancer-specific 
mortality.8 Prior research shows that patients with serious comorbidities have outcomes 
that are comparable to those observed in the later stages of tumor.14  A Danish 
nationwide study concluded that successful treatment of existing co-morbidities in 
breast cancer patients can improve survival rates of the patients.7 Non-cancer mortality 
is higher in black patients than whites at ages younger than 70.15 Another study showed 
that carefully accounting for comorbid illnesses, particularly diabetes and hypertension, 
explained much of the racial disparity in non-cancer mortality.16  
 
Specific Co-Morbidities. 14 African American women are considered at higher risk of 
chronic conditions such as diabetes, hypertension and cardiovascular disease.7 
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Measures of specific comorbidities may reflect the survival outcome more clearly than 
do summarized measures that often give the same weight to all morbidities despite their 
different impact. Age-adjusted death rates for coronary heart disease and stroke has 
been shown to be higher in African Americans.22 These factors can very well raise the 
risk of overall mortality and breast cancer specific mortality.  
In recent years, more and more researchers have started looking at co-morbidities at 
diagnosis of breast cancer that may explain survival outcomes in black patients. These 
conditions as previously mentioned can be preexisting diabetes, hypertension, obesity 
and number of other common chronic diseases. Preexisting conditions, though 
unrelated to breast cancer, can pose a great threat to overall survival. A Black/White 
Cancer study has shown that uncontrolled co-morbidities have an adverse effect on 
cancer treatment and cancer survival outcomes.25  
African American women have suboptimal blood pressure control based on 
Healthy People of 2010 standards. As many as 64% of African American women may 
have uncontrolled hypertension.27 In Blacks, severe hypertension and targeted organ 
complicated hypertension are more common than in whites. Both are associated with 
cardiovascular disease. Black Americans have a much higher risk of experiencing 
hypertension related complications such as nephropathy, stroke, heart failure and type 
2 diabetes.28 A study conducted in 2007 across 12 southeastern states found that the 
pattern of treatment of diabetes in Black patients results from  “suboptimal 
implementation of evidence-based hypertension treatment guidelines”.31 Randomized 
controlled studies have shown adequate blood pressure control in African Americans 
who receive and adhere to optimal evidence-based hypertensive treatment with dietary 
changes, ruling out biological differences as the root cause. Similarly, diabetes in 
combination with hypertension is also a major public health problem in African 
Americans. African Americans with diabetes are three times more likely to have 
uncontrolled hypertension than those without diabetes.29 The CDC estimates that black 
women have a 90% higher prevalence of diabetes than white women. The burden of 
diabetes disproportionally affects blacks with more black women ending up with end-
stage-renal diseases than white women. Black women have also had 22% highest 
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hospitalization rate related to diabetes in the 1990s compared to black men and a 
striking 215% higher than white women.30  
A recent study showed that breast cancer patients with a history of diabetes have 
an increased risk of breast cancer specific mortality.26 Results from this study estimated 
a 2-fold increase in breast cancer-specific mortality if diabetes was not treated in breast 
cancer patients. Similarly, history of myocardial infarction was found to increase the risk 
of breast cancer specific mortality. This pattern was observed in African Americas, 
Asian Americans and Latinas.26 Additionally, those with a history of diabetes had a 
significantly elevated risk of breast cancer specific mortality without chemotherapy or 
radiotherapy compared to those without a history of diabetes and without 
chemotherapy.  More so, breast cancer specific mortality was significantly elevated 
among cases with diabetes that didn’t receive chemotherapy versus those without 
diabetes and chemotherapy.26 Diabetes and hypertension have been strongly and 
widely associated with obesity.33,34  More than 75% African American women are 
overweight or obese.34 
 
Tumor Burden and Biology. Advanced stage at diagnosis also has been examined as 
an explanatory factor in survival disparity. African American women are typically 
diagnosed at an advanced stage and at younger ages even though the mammography 
utilization and screening rate is comparable in whites and blacks.18 Advanced disease, 
however, does not explain the survival gaps because the survival disparities are found 
within each stage and not just at the advanced stage level 3.  
In the past decade, adverse tumor biology has emerged as a focus in breast 
cancer disparities emerged.17 In particular, African American/black women have three-
fold greater prevalence of triple negative breast cancer (TNBC) compared to white 
women 1,19 TNBC tumor lacks the expression of estrogen, progesterone and HER2 
receptors in breast cancer cells. Receptors are found on cancer cells and attach to 
certain substances such as hormones that circulate in the blood. Some breast cancer 
cells have receptors that bind to estrogen or progesterone hormones. Estrogen and 
progesterone hormones are both known to fuel the growth of breast cancer cells. Breast 
cancer cells that either express receptors for estrogen or progesterone are known as 
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hormone-receptor positive breast cancer. Almost 20% of breast cancer patients have a 
breast cancer cell growth protein called HER2/neu that promotes the growth of cancer 
cells. Breast cancer cells that express increased levels of HER2/neu proteins are 
classified as HER2 positive and tend to grow more aggressively compared to other 
cancers. The hormone receptor positive and HER2/neu positive breast cancer have 
targeted hormonal therapy, and therefore have better prognosis.3 Because TNBC 
tumors lack hormone receptors, no hormonal therapy is useful. When compared to 
other subtypes of cancer tumors, TNBC tumors have been shown to result in 
significantly worse prognosis outcomes9.  However, a recent study shows that African 
American women with breast cancer continue to experience survival disadvantages in 
advanced disease whether or not the tumor expresses the TNBC subtype.20 This 
evident suggests that other clinical and psychosocial factors must be studied to fully 
understand the survival gap. Recently, presence of co-morbidities has emerged as a 
potential risk factor for the African American women with breast cancer 21. 
 
Hypotheses. Based on our prior research that showed evidence of co-morbidities being 
the independent prognosis factor for African American with breast cancer1, we 
hypothesize that there is an association between co-morbidities and specific cause of 
death in African American breast cancer patients. We anticipate that African Americans 
are more likely to die of non-breast cancer related causes such as heart disease or 
diabetes compared to white breast cancer patients. Hence, in our total sample 
(n=2558), we predict that competing risk factor analyses will reveal differences in cause-
specific death mortality between blacks and whites. Second, given that it is likely that 
the survival disparities in African Americans breast cancer patients might be due to the 
higher chances of dying from the existing co-morbidities at breast cancer diagnoses, we 
expect to see a positive relationship between the co-morbidity score and mortality 
hazard ratio resulting from one or the combination of those co-morbidities as analyzed 
in the sub-sample (n=416) of the chart review. We predict that these patterns will be 
independent of TNBC status and breast cancer stage.  
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METHODS: Study population: Our overall sample consists of all AA/B breast cancer 
cases (ICD-O-3 C50.0-C50.9)  diagnosed between January 1, 2000 and December 
31,2007  and an age-matched random sample of an equivalent number of white 
patients during the study period (n=2558). From this sample and a random sample 
(n=416) medical record review on African American (AA/B) and White female breast 
cancer patients. The random sample of 416 female breast cancer patients is derived 
from our parent study (full sample) of 2558 patients diagnosed with primary breast 
cancer (ICD-O-3 C50.0-C50.9) between January 1, 2000 and December 31, 2007 in the 
State of Connecticut.  Data were obtained from the Connecticut Tumor Registry (CTR), 
a participant site in the NCI-SEER program. In statistical analyses for n=416, we 
excluded patients who had missing data on age, race, TNBC status, comorbidity score, 
vital status, Seer Summary stage advance/distant and those who were lost to follow up. 
Access to medical records was approved by the Institutional Review Boards at 
University of Connecticut Health Center, Yale Cancer Center, Hartford Hospital, and the 
Human Investigation Committee at the Connecticut Department of Public Health. 
 
Causes of Death:  Case records were followed untill December 2015 for vital statuses 
including causes-of-death. Causes of deaths were grouped into five categories including 
breast cancer, cardiovascular diseases, non-cardiovascular diseases, other cancers 
and unknown causes. 
Descriptive Analyses: Clinicopathological characteristics between white and AA/B 
patients are compared for full sample (n=2558) and random sample (n=416) using χ2 
test for the following categorical variables: age, histological subtype, SEER summary 
stage, tumor grade and TNBC. SEER summary stage distant will be excluded from 
parent population for survival analyses.   
 
Clinicopathological Data. Information in the CTR database includes: ER, PR, age at 
diagnosis, SEER Summary Stage (local, regional) and ICD-O-3 histologic subtypes. 
Local stage is defined in SEER as invasive cancer confined to the breast; and, regional 
stage is defined, as cancer detected to have spread to the axillary lymph nodes or 
contiguous tissue. Information about first-course of chemotherapy is available in the 
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CTR database, although in recent years SEER no longer makes this information 
available in the public dataset due to substantial missing data and unreliability of the 
information.37 TNBC status was derived from both the CTR database (i.e., ER, PR) and 
abstraction of summary pathology reports (i.e., HER2) at the registry as described in our 
previous investigations using this study sample.28   
 
Co-Morbidity Information.  Medical conditions were abstracted using the validated 
Charlson Co-Morbidity Index (CCI), a weighted list of 17 items developed in 198740 and 
a prominent tool in cancer research.41 The CCI includes measurement of  myocardial 
infarction, congestive heart failure, peripheral vascular disease, cerebral vascular 
disease, dementia, chronic lung disease, rheumatologic disease, peptic ulcer disease, 
mild liver disease, diabetes without complications, diabetes with complications, 
hemiplegia, neoplasia, moderate/severe liver disease, metastatic disease, human 
immunodeficiency virus, and renal disease.  A cumulative score is calculated based on 
a no (0) or yes (1) for each condition, and weighted according to a specific protocol.40 
Briefly, the weight applied to a particular condition reflects the associated hazard ratio of 
death within one-year of cancer diagnosis.  
 Due to emerging evidence of the prognostic importance of hypertension in 
distinguishing mortality risk in cancer survival disparities38, we adopted the CCI 
following an approach in Braithwaite and Tammemagi39 to assign an additional point by 
including high blood pressure (CCI+HBP) as comorbidity. Scores for the CCI (0-17) and 
CCI+HBP indices were employed in statistical analyses as either a continuous or 
categorical variable (0, 1-2, ≥ 3). We will look at the weight distribution of AA/B and 
whites for CCI score with hypertension and compare the differences between the two.   
 
Competing Risks Survival Analyses:  Survival time is measured for all patients as the 
duration of date of diagnoses to date of death or last follow up.  When conducting a 
competing risk analyses, patients still alive at the date of last follow up are considered 
‘censored’ and those who died of a disease under study are considered an ‘event’. 
Patients who die of an unrelated cause are considered competing risk events.6  
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Kaplan-Meier or cause-specific method estimates the distribution of time to event of 
interest such as death from breast cancer and ignores all the other events This method 
censors all competing events and may yields biased results. While a cause-specific 
model is better suited for examining the etiology of diseases, the subdistributional 
hazard ratio model is more useful in predicting an individual’s competing-risks.35 In this 
model, those subjects that experience a competing risk event are retained even after 
the competing event but with gradually decreasing weight.35-36 We used The Fine and 
Gray subdistributional hazard ratio (described elsewhere)35 to compare the absolute 
mortality risk for breast cancer and all-cause deaths for the full sample (n=2558) and to 
asses AA/B versus White breast cancer patients’ mortality in the presence of competing 
risks by age and tumor size for local and regional stages. Briefly, in this model the 
hazard ratio is based on a modified risk set where those subjects that experience a 
competing event remain in the risk set even after experiencing that event. The weight of 
the subjects that are retained in the risk set artificially reduces gradually. SAS edition 
9.0 was used for Phreg functions analyzing subdistributional hazard ratio and standard 
cox/cause specific hazard model.42 We also applied the subdistributional hazard model 
for breast cancer and all cause deaths in AA/B verses White breast cancer patients by 
age, tumor size for the subset analyses (n=416) with and without co-morbidity index 
score in the model. We used the standard cox regression/cause-specific hazard model 
for all-cause mortality and by breast cancer-specific death in AA/B and white breast 
cancer patients by multivariate age and tumor size for the full sample. Cause-specific 
hazard model was used for the sub-sample (n=416) by multivariate age and tumor size 
with and without Co-morbidity score (+/-). In order to infer the added benefits of co-
morbidity in analyzing competing risk hazard ratio for breast cancer, we compared the 
differences in hazard ratio using cause-specific model and subdistributional model for 
breast cancer specific mortality in AA/B and Whites between full sample and sub-
sample with co-morbidity index score at the local stage.  
Next, we explored all-cause and breast cancer specific Co-morbidity index hazard ratio 
using cause-specific model for AA/B and whites by multivariate age, co-morbidity index 
score, and tumor size at local and regional stages in the presence of competing event. 
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Risks to human subjects: Data collected for this project is from Connecticut tumor 
registry located in the department of public health. By legislation law, all licensed 
Connecticut hospitals are required to provide information on cancer incidence, 
treatment and follow up. The Connecticut General Statue 19a-25 protects the identities 
of all the human subjects/patients. Confidentiality and privacy of subjects is approved by 
the Investigations Committee of the Connecticut once reviewing the study’s protocol, 
methods and procedures for protecting the patient’s privacy and confidentiality. 
Completely anonymous data is used with unique study ID numbers for all individuals to 
safeguard subject’s privacy. No such data is used that might lead to a particular 
individual’s bio-data.  
 
RESULTS 
In the total sample n=2558 (Table1), the most common histology subtype in both whites 
and AA/B was ductal (67.1% and 68.6%, respectively) yet the overall histological 
patterns were statistically significant (P <.0001 omnibus) due to variations in prevalence 
of lobular and medullary sub-types. Compared to black patients, white patients were 
almost twice as likely to have lobular histology, which is comparatively more favorable 
histology (10.3% vs. 5.6%, respectively, p<0.0001) and less likely to be diagnosed with 
the more aggressive medullary breast cancer (0.4% vs. 8.1%, p<.0001). Similar trends 
were observed in the n=416 subsample (Table 1). As expected, white patients were 
more likely than blacks to have early stage disease in both the full (65.8% vs. 57.1%, 
respectively, p<0.0001) and sub-sample (68.7% vs. 62.0%, respectively p=.0.209) but 
the difference reached statistical significance in the full sample (Table 1). AA/B breast 
cancer patients had a higher prevalence of TNBC in the total sample as well as 
subsample n=416 (30.3% vs. 12.8% p<0.0001 and 26.0% vs. 16.4% p<.001) 
 
Charlson Co-Morbidity Index (n=416 sub-sample):  
AA/B breast cancer patients were more likely to have higher CCI scores (Table 2, 
omnibus p<.0001) as determined by the weighted sum of conditions present within one-
year (before and after) the breast cancer diagnosis. Specifically, substantially more 
white breast cancer patients had no existing co-morbidity compared to black patients 
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(82.7 % vs. 58.9%, respectively, p,.0001); 25.7% of AA/B had a CCI score of 1-2 
compared to only 11.2% of whites (p<0.0001); and, proportionally more AA/B 
Americans had CCI scores of 3 or more compared to their white counterparts (15.3% 
vs. 6.1% p<0.0001). When hypertension was added to the index, the proportion of AA/B 
patients without any co-morbidity decreased by one-third (58.9% to 39.1%), and, for 
white patients, the drop was about one-fourth (82.7% to 60.7%). 
 
Causes of Death: 
The median survival time after diagnosis was comparable (10.4 vs. 10.2 yrs) for both 
AA/B and whites in the full and sub-samples (Table 3). While breast cancer was the 
leading cause of death in both AA/B patients and white patients in the sub-sample 
(Table 3), somewhat more AA/B patients died of breast cancer compared to whites 
(50.7% vs 43.8%, omnibus P=.810)   
 
All-Cause Hazard Ratio:  
Among patients diagnosed with local stage of breast cancer (i.e., tumor has not spread 
to regional lymph nodes), AA/B did not appear to be at increased risk of mortality 
compared to whites in the full (Crude HR=0.973, 95% CI 0.872-1.087) or sub-sample 
(Crude HR=0.955, 95% CI =0.741-1.231) (Table 4). When adding the standard CCI 
score to the analysis, the HR estimate did not appreciably change. At the regional 
stage, AA/B patients were found to be at increased risk for overall death in full sample 
(HR=1.310, 95% CI= 1.128-1.522). Regarding patients diagnosed with regionally 
advanced breast cancer, adding CCI did not change the all cause mortality ratio for 
AA/B women (HR=1.006, 95% CI= 0.691-1.466).  
 
Breast Cancer Specific Hazard Ratios 
For the full sample, as seen in Table 5, blacks were more likely to die from breast 
cancer when analyzed with the sub-distribution analysis methodology (SD-HR=1.434 
95% CI 0.969-2.122) yet no effect was revealed using the traditional Cox Proportional  
Hazards Survival analysis (HR= 0.966, 95% CI=0.865-1.079). This difference in 
findings, however, was not observed when analyzing the sub-sample in which no black-
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white difference in survival was observed by either method. When adding the CCI score 
to the model, the traditional method revealed no black-white difference in dying from 
breast cancer yet the risk of death from breast cancer among blacks compared to 
whites was significantly reduced when using the subdistributional model (HR=0.168, 
95% CI 0.0310-0.902).  
For patients diagnosed with regional disease in the full sample, AA/B show an 
increased risk of death from breast cancer compared to whites (HR=1.307, 95% 
CI=1.125-1.519). Subdistributional model also shows a heightened increased risk of 
breast cancer specific mortality for AA/B at regional stages (HR=1.841, 95% CI 1.339-
2.530). Adding CCI in the multivariate model suggests an increased risk of breast 
cancer specific mortality for AA/B compared to whites when using the sub-distribution 
model only (HR=1.999, 95% CI 0.902-4.346). Findings in Table 5 are illustrated 
graphically in Fig 1.a (full sample) and Fig 1.b (sub-sample). 
Risk of breast cancer specific death in relation to Charlson Comorbidity: As an 
independent factor, the CCI was associated with statistically significant increases in the 
hazard ratio per one unit score using both statistical methods for patients with local 
disease (HR=1.363 95% CI 1.223-1.518 and SD-HR=2.088 95% CI 1.633-2.67) and for 
regional disease (HR=1.132 95% 1.034-1.240 and SD-HR 1.167 95% CI 1.063-1.280). 
 
DISCUSSION: 
  
In order to diminish inequities in survival among breast cancer patients, it is 
important to understand the role that existing co-morbidities play in mortality given 
higher rates of various conditions among AA/B patients. We addressed this issue in two 
ways: 1) Incorporating a co-morbidity score (CCI) into multivariate analyses; and, 2) 
Assessing if African-Americans tend to die at a higher proportion from breast cancer 
versus co-morbidities (e.g, heart disease). Additionally, when evaluating cause-specific 
deaths, we compared the use of traditional cox-regression model, which censors non-
breast cancer deaths with the subdistributional hazard model, which takes into account 
all causes of deaths.  
Descriptive Analyses. Using the Charlson Co-Morbidity Index, our descriptive 
analyses showed that African Americans breast cancer patients were far more likely to 
have an existing co-morbidity at the diagnosis compared to whites. Specifically, about 
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41% of AA/B patients had at least one co-morbidity at diagnosis compared to 17% of 
whites. This prevalence appears somewhat consistent with a Medicare claim data 
analyses that had shown that almost 42% of patients diagnosed with breast cancer has 
one or more co-morbidities.46 This difference in comorbidities at the diagnoses of breast 
cancer is not due to the differences in age between AA/B and whites. Whites are 
diagnosed at an older age and should have higher number of existing comorbidities yet 
AA/B still experience higher rates of existing comorbidities despite being diagnosed with 
breast cancer at a younger age. The Charlson co-morbidity index does not include 
hypertension in its 17-listed comorbidities, and based on a prior study by Braithwaite et 
al39 we added hypertension for comparative analyses. As expected, the score for AA/B 
breast cancer patients increased disproportionally compared to the increase in white 
patients.  
Causes of death between African American and whites showed marked differences as 
well. In the larger study group (n=2558), AA/B experienced higher rates of death from 
breast cancer compared to whites. However, in the smaller group of n=416 with 
comorbidity index included, the difference between blacks and whites was reduced.  A 
possible reason could be that rate of co-morbidities differed between the two study 
samples, although we employed a randomization scheme to create the smaller sample 
for the chart review.  We base this hypothesis on prior studies that have shown, 
paradoxically, that delays or under treatment for conditions such as diabetes and 
myocardial infarction can actually result in increased breast cancer specific mortality26.  
More so, it is well-established that AA/B have a higher prevalence of undertreated and 
uncontrolled diabetes. 31 
Survival Analyses. We employed the traditional Cox Proportional Hazards regression 
model and, for comparison, the subdistributional hazard model, which has been found 
to provide a more accurate estimate of risk when there is a high degree of deaths from 
other causes in the study population (i.e., competing risks).46-48 Among patients 
diagnosed with Local Stage disease, when the traditional Cox method with breast 
cancer specific mortality as the end-point (all other endpoints censored) was employed 
in the larger sample (n=2558), we observed comparable mortality risks for African 
American and whites (HR=0.966 95% CI 0.865-1.079), yet the subdistributional method 
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showed an increase in breast cancer mortality risk for African Americans (SD-HR=1.434 
95% CI 0.969-2.122). The corresponding estimates for Regional Stage were (HR=1.307 
95% CI 1.125-1.519 and SD-HR=1.841 95% CI 0.1.339-2.530). It appears, therefore, 
that the traditional model appears to have indeed overestimated hazard mortality for 
whites. On the other hand, the analyses for the small sample (n=416), did not show 
these patterns, and showed a reduced risk of breast cancer specific mortality among 
blacks compared to whites (SD-HR=0.17 95% CI 0.03-0.92) at the local level. The Cox   
method however revealed no differences (HR=0.97 95% CI 0.70-1.17). 
Regarding the addition of co-morbidity scores into the multivariate models, we 
observed that at the local stage breast cancer-specific mortality for AA/B was 
significantly reduced suggesting that existing comorbidities might drive mortality when 
the cancer burden is low. Racial disparities in breast cancer-specific mortality were also 
noted when using the subdistribution analysis in Regional Stage with higher breast 
cancer-specific mortality, pointing towards a greater burden of death at the advancing 
stage. The impact of comorbidities is prevalent in local stage versus the regional stage 
possibly due to the increased mortality risk resulting from the added anatomical burden 
of regional disease. This is consistent with our previous findings from 2015 that 
emphasized the role of existing conditions as playing a role for AA/B in worsening their 
survival outcomes particularly at the local stage level. Prior studies also have shown 
that the presence of a co-morbidity at the time of diagnosis of breast cancer have 
significantly worse survival outcomes.14 The combined effects of advanced stage and 
existing comorbidities for AA/B compared to whites suggests a possible additive or 
multiplicative effect.  
Our findings are not consistent, however, with Schairer and colleagues who have 
shown a lower breast cancer specific mortality at regional stage with advanced age. 
Other studies have shown a larger effect of all cause mortality with advancing age.50-51. 
While Schairer et al did not account for comorbidities, they speculated that higher 
probability of death from breast cancer and other causes in blacks compared to whites 
might also be attributed to obesity related morbidities.49 Breast cancer-specific mortality 
showed results that were independent of age, breast cancer subtype and race. AA/B 
race was not a prognostic factor for worsening breast cancer-specific mortality hazard 
 15 
ratio but rather the advancing stage and comorbidities seem to play a role. Adding the 
Charlson Co-morbidity Index in the model showed significant differences for AA/B risks 
for breast cancer mortality at the local stage. Other studies have also shown an 
increase in mortality rate from other causes with advancing age.49-50 There are also 
reports that look at 5 to 8 year relative survival showing no decline in breast cancer 
mortality with advancing age.51-52 
Further exploration can point towards treatment differences, poorly controlled 
conditions and possibly genetic differences such as higher prevalence of sickle cell 
anemia. African Americans have a high prevalence of sickle cell trait. Results from 
National Surgical Adjuvant Breast and Bowel Project (NSABP) showed that stage and 
pathological differences did not fully account for differences in outcome between African 
Americans and white women with breast cancer. In addition when stage and treatment 
was comparable, blacks and white breast cancer patients had similar outcomes. 
Despite the fact that clinical differences are important for breast cancer survival 
prognosis, appropriate and timely treatment may yield better outcomes for African 
American women with breast cancer.43 Previous literature review and case reports have 
shown adverse events in breast cancer patients with sickle cell trait possibly due to 
higher chances of hypoxia and sickling resulting from cancer therapy. Literature 
indicates that in the presence of sickle cell trait, enhanced patient monitoring and 
treatment adjustment is needed. Furthermore, genotyping might be another necessary 
step for African Americans with breast cancer prior to treatment.44-45    
African women also experience high CCI hazard ratio breast-cancer specific mortality 
rate due to existing comorbidities at the local stage. White Americans with the same 
comorbidity index score, not showing the same detrimental increase in CCI hazard 
compared to African American women, may indicate that presence of poorly controlled 
conditions like hypertension, cardiovascular disease and diabetes can be responsible 
for worse breast cancer specific outcomes for African Americans. It may also be due to 
certain genetic predispositions such as sickle cell trait that has been overlooked. In 
addition, it reinforces the need to further investigate the clinical and pathophysiological 
differences in existing conditions between different racial groups.  
Public health implications: 
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Complex and interwoven factors contribute to observed disparities in breast cancer 
deaths among racial and ethnic minorities. The probability of death from causes other 
than breast cancer in the presence of competing risks appears to be a more accurate 
measure of mortality across different ethnicity/racial group. While socioeconomic factors 
have been under extensive study, existing conditions such as cardiovascular disease 
and diabetes are the emerging competing risks that play a role in cancer survival and 
treatment.  One of the main goals of public health is to eliminate health disparities using 
improved prognostic information by assessing the burden of mortality from breast 
cancer and other causes by race and comorbidities. Studying breast cancer survival 
differences among the racial minority help us draw a map of the contributing factors and 
their possible solution. This study will help to elucidate if AA/B and white differ in 
competing risks for breast cancer mortality and all-cause mortality. By understanding 
the risks, we can focus on reducing these risk factors in both African American and 
white breast cancer patients.  
Strengths and Limitations:  
We had multiple strengths in our study. Our population was derived from reputable NCI-
SEER Tumor registry of Connecticut. One of the strength of our analyses was 
establishing a comorbidity index score for our breast cancer patients with the addition of 
hypertension, which confirmed higher rates of co-morbidities scores for AA/B vs. Whites 
at the time of breast cancer diagnoses. Our n=416 sample was comparable to our larger 
study population and showed similar histopathological findings. More so, our 
histopathological findings such as TNBC subtype and tumor subtypes were concurrent 
with other cancer survival studies. There are two main limitations to this study. One 
limitation of this study was sample size due to which we were not able to look at specific 
co-morbidities such as diabetes and myocardial infarction separately. Another limitation 
that came with the small sample was not having large enough numbers of 
cardiovascular or diabetes deaths. Therefore, the causes of death had to be studied as 
breast cancer versus non-breast cancer. Lack of treatment data is another potential 
limitation given that a number of studies have shown that different treatment patterns 
may explain some survival disparities in breast cancer.  
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 White 
n=1405 
AA/B 
n=1152 
 P-Value 
 
White 
n=214 
AA/B  
n=202 
P-Value 
Age 
<=40 
 
>40 
 
 
80 
5.8% 
1285 
94.1% 
 
123 
10.8% 
1011 
89.1% 
 
 
 
<.0001 
 
  11 
5.1% 
203  
94.8% 
 
30 
14.8% 
172 
85.1% 
 
 
 
0.005 
 
Mean Age 
(SD) 
62 
54.9% 
57 
45.1% 
 
.721 
58 
51.4% 
55 
48.6% 
 
<.0001 
Histological Subtype *  
Ductal 
 
Lobular 
 
Mixed (Ductal, Lobular ) 
 
Medullary 
 
Other 
 
 
 
907 
67.1% 
139 
10.3% 
191 
14.1% 
6 
0.4% 
109 
8.1% 
 
777 
68.6% 
63 
5.6% 
143 
12.6% 
33 
2.9% 
116 
10.2% 
 
 
 
 
<.0001 
 
124 
57.9% 
24 
11.2% 
52 
24.3% 
2 
0.9% 
12 
5.6% 
 
127 
62.9% 
12 
5.9% 
37 
18.3% 
4 
2.0% 
20 
10.9% 
 
 
 
  
0.043 
 
SEER Summary Stage 
Local 
 
Regional 
 
 
 
885 
65.8% 
393 
29.2% 
 
 
637 
57.1% 
411 
36.9% 
 
 
 
<.0001 
 
145  
68.7% 
 66  
 31.3% 
 
 
119 
 62.0% 
73  
38.0% 
 
 
 
 0.209 
 
TNBC subtype  
ER-  PR-  HER2- 
  
ER-  PR-  HER2+ 
  
ER / PR+ HER2- 
  
ER / PR+ HER2+ 
  
 
117 
12.8% 
39 
4.3% 
637 
69.7% 
121 
13.2% 
 
243 
30.3% 
80 
10.0% 
397 
49.6% 
81 
10.1% 
 
 
<.0001 
 
35 
16.4% 
6  
2.8% 
143 
66.8% 
30  
14.0% 
 
52  
25.7% 
20 
9.9% 
117 
57.9% 
13  
6.4% 
 
 
<0.0001 
 
 
 
 
  
N=2558 N=416 
Table 1a: 
 
Clinicopathological Characteristics of Breast Cancer Patients 
(According to Race, Age, NCI SEER Tumor Registry, and TNBC) 
 
 18 
  
  
White Black P Value 
CCI score 
0 
 
1-2 
 
3+ 
 
 
177 
82.7% 
24 
11.2% 
13 
6.1% 
 
 
119 
58.9% 
52 
25.7% 
31 
15.3% 
 
 
 
<.0001 
CCI score with HBP 
0 
 
1-2 
 
3+ 
 
 
 
130 
60.7% 
64 
29.9% 
20 
9.3% 
 
79 
39.1% 
84 
41.6% 
39 
19.3% 
 
 
 
<.0001 
Table 2 CCI score with and without HBP (n=416)  
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N=2558 
 
P-Value 
 
N=416 
 
P-Value 
White Black  White Black  
 
Alive 
 
913 
65.4% 
 
687 
60.5% 
 
.011 
 
166 
77.6% 
 
31 
65.8% 
 
.008 
Median Survival 
(years) 
 
10.2 
 
10.4 
  
9.7 
 
10.3 
 
Cause of Death 
 
Breast Ca 
 
 
Other Ca 
 
 
CVD 
 
 
Non-CVD 
and Other/Unk 
 
 
182 
37.7% 
 
63 
13.0% 
 
86 
17.8% 
 
152 
31.5% 
 
 
225 
50.1% 
 
55 
12.2% 
 
64 
14.3% 
 
105 
23.3% 
.001 
 
 
21 
43.8% 
 
8 
16.7% 
 
6 
12.5% 
 
13 
27.1% 
 
 
35 
50.7% 
 
8 
11.6% 
 
7 
10.1% 
 
19 
27.5% 
.810 
Table 3  Vital Status, Survival and Cause of Death in relation to Whites and AA/B 
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Table 4  Multivariate* All-Cause Hazard Ratios and 95% CIs with and without 
Charlson Co-Morbidity Index (CCI) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 5 Multivariate* Breast Cancer Specific Hazard Ratios and 95% CIs with and 
without Charlson Co-Morbidity Index 
 
 
n=2558 
 
 
n=416 
  
HR 
 
SD-HR 
 
HR 
 
SD-HR 
Black vs White 
Local Stage 
No CCI 0.966 
0.865-1.079 
 
1.434 
0.969-2.122 
0.955 
0.739-1.233 
0.870 
0.290-2.613 
With CCI   0.906 
0.700-1.173 
 
0.168 
0.031-0.902 
Regional Stage 
No CCI 1.307 
1.125-1.519 
1.841 
1.339-2.530 
1.061 
0.733-1.535 
 
2.378 
1.106-5.113 
With CCI   0.980 
0.671-1.429 
 
1.999 
0.902-4.346 
                                                           CCI HR 
Local Stage 1.363 
1.223-1.518 
 
2.088 
1.633-2.670 
Regional Stage 1.132 
1.034-1.240 
 
1.167 
1.063-1.280 
  
             
n=2558 
 
n=416 
 
n=416 
Local Stage 
 Black vs. White 
HR 
Black vs. White 
HR 
Black vs. White 
CCI HR 
No CCI .973 
0.872-1.087 
0.955 
0.741-1.231 
 
With CCI  - 0.906 
0.700-1.173 
1.363 
1.223-1.518 
Regional Stage 
No CCI 1.310 
1.128-1.522 
1.088 
0.753-1.572 
 
With CCI - 1.006 
0.691-1.466 
1.129 
1.032-1.236 
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